Enrolment in the EURO SHOCK trial was curtailed due to the COVID-19 pandemic, but the results of the trial show “promise” and should inform future research, investigator Manel Sabate (Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain) tells Cardiovascular News.
The trial sought to determine if the early use of veno-arterial extracorporeal membrane oxygenation (V-A ECMO) in patients with persistent cardiogenic shock receiving primary percutaneous coronary intervention (PCI) could improve outcomes.
Speaking at EuroPCR 2023 (16–19 May, Paris, France) where the results were presented for the first time, Sabate outlined the potential benefits employing ECMO in the setting of cardiogenic shock, and offered insights from the trial, which though curtailed due to the pandemic, could offer important insights.
